Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab

BACKGROUND: Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. To attempt to identify prognostic and predictive biomarkers, ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuchs, Charles S, Tabernero, Josep, Tomášek, Jiří, Chau, Ian, Melichar, Bohuslav, Safran, Howard, Tehfe, Mustapha A, Filip, Dumitru, Topuzov, Eldar, Schlittler, Luis, Udrea, Anghel Adrian, Campbell, William, Brincat, Stephen, Emig, Michael, Melemed, Symantha A, Hozak, Rebecca R, Ferry, David, Caldwell, C William, Ajani, Jaffer A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061911/
https://www.ncbi.nlm.nih.gov/pubmed/27623234
http://dx.doi.org/10.1038/bjc.2016.293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061911/
https://www.ncbi.nlm.nih.gov/pubmed/27623234
http://dx.doi.org/10.1038/bjc.2016.293

Ejemplares similares